Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen BiotechnologyROCO:3176 -4.26%58 Debt-to-Equity is 0.36 as of Jun. 2026, which is 48% below its 10-year median of 0.69. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$33.03 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 966 Biotechnology companies, Medigen Biotechnology ranks worse than 89.03% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medigen Biotechnology's Debt-to-Equity or its related term are showing as below:
ROCO:3176'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.38 Med: 0.69 Max: 1.87
Current: 1.16
During the past 13 years, the highest Debt-to-Equity Ratio of Medigen Biotechnology was 1.87. The lowest was 0.38. And the median was 0.69.
ROCO:3176's Debt-to-Equity is ranked worse than 89.03% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs ROCO:3176: 1.16
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medigen Biotechnology Debt-to-Equity Related Terms
Medigen Biotechnology Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Debt-to-Equity of 0.36 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medigen Biotechnology and its competitors. This is 48% below median its historical median of 0.69. Over the past decade, Medigen Biotechnology's Debt-to-Equity has ranged from 0.38 to 1.87. According to the industry distribution chart, Medigen Biotechnology ranks #860 out of 966 companies in the Biotechnology industry, placing it in the top 89%.
Is Medigen Biotechnology's Debt-to-Equity too high?
Medigen Biotechnology's current Debt-to-Equity of 0.36 is 48% below median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 1.87. The Biotechnology industry median Debt-to-Equity is 0.15. Medigen Biotechnology's value of 0.36 is 140% above this industry median. Based on the distribution chart, Medigen Biotechnology ranks #860 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #860 out of 966 companies for Debt-to-Equity. This places Medigen Biotechnology in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Medigen Biotechnology's value of 0.36 is 140% above this benchmark. Historically, Medigen Biotechnology's own Debt-to-Equity has ranged from 0.38 to 1.87 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 0.15, Medigen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Biotechnology's current Debt-to-Equity of 0.36 is 140% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current Debt-to-Equity is 0.36, which is 48% below median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$33.03, compared to a current price of NT$38.20 — trading 15.7% above its estimated fair value. The current Debt-to-Equity is 0.36, which is 48% below median its 10-year median of 0.69 and 140% above the Biotechnology industry median of 0.15. Medigen Biotechnology's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Debt-to-Equity is 0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be overvalued.
The current stock price of NT$38.20 is trading 15.7% above its estimated GF Value™ of NT$33.03.
GuruFocus considers Medigen Biotechnology to be Modestly Overvalued.
Key valuation signals for ROCO:3176:
Debt-to-Equity: 0.36 (48% below median its 10-year median of 0.69)
GF Value™: NT$33.03 vs. price of NT$38.20 (15.7% above fair value)
Industry Position: 140% above the Biotechnology median (#860 of 966)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
